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In recent years, there has been a rapid dissemination of carbapenem resistant 
Enterobacteriaceae (CRE). This study aimed to compare phenotypic and molecular 
methods for detection and characterization of CRE isolates at a large tertiary care 
hospital in Saudi Arabia. This study was carried out between January 2011 and No-
vember 2013 at the King Khalid University Hospital (KKUH) in Saudi Arabia. De-
termination of presence of extended-spectrum beta-lactamases (ESBL) and carbap-
enem resistance was in accordance with Clinical and Laboratory Standards Institute 
(CLSI) guidelines. Phenotypic classifi cation was done by the MASTDISCSTM ID 
inhibitor combination disk method. Genotypic characterization of ESBL and car-
bapenemase genes was performed by the Check-MDR CT102. Diversilab rep-PCR 
was used for the determination of clonal relationship. Of the 883 ESBL-positive 
Enterobacteriaceae detected during the study  period, 14 (1.6%) isolates were car-
bapenem resistant. Both the molecular genotypic characterization and phenotypic 
testing were in agreement in the detection of all 8 metalo-beta-lactamases (MBL) 
producing isolates. Of these 8 MBL-producers, 5 were positive for blaNDM gene and 
3 were positive for blaVIM gene. Molecular method identifi ed additional blaOXA gene 
isolates while MASTDISCSTM ID detected one AmpC producer isolate. Both meth-
ods agreed in identifying 2 carbapenem resistant isolates which were negative for 
carbapenemase genes. Diversilab rep-PCR analysis of the 9 Klebsiella pneumoniae 
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isolates revealed polyclonal distribution into eight clusters. MASTDISCSTM ID is a 
reliable simple cheap phenotypic method for detection of majority of carbapenemase 
genes with the exception of the blaOXA gene. We recommend to use such method in 
the clinical laboratory.
Keywords: Enterobacteriaceae, carbapenem resistance, Modifi ed Hodge 
Test, blaNDM gene, blaVIM gene, blaOXA gene, molecular characterization, Check-
MDR, DNA microarray, MASTDISCSTM ID
Introduction
The rapid dissemination of extended-spectrum beta-lactamase (ESBL)-
producing bacteria has led to the increased utilization of carbapenems as antimi-
crobials of last resort for the treatment of infections caused by these multidrug 
resistant (MDR) microorganisms [1]. Thus in recent years, carbapenem-resistant 
Enterobacteriaceae (CRE) harbouring resistance genes for carbapenemases 
have emerged as major causes of nosocomial infections globally [2–3]. Among 
isolates reported to the National Healthcare Safety Network (NHSN) in 2009 
and 2010, carbapenem resistance was reported in up to 77.2% of Escherichia coli 
and Klebsiella pneumoniae [4]. Clinically signifi cant carbapenmases in Entero-
bacteriaceae, are the Ambler molecular Class A (KPC), Class B (VIM, IMP, 
NDM) and Class D (OXA-48) types [5]. Infections caused by CRE harbouring 
these resistance genes have limited treatment options, spread easily in health-
care settings and are associated with high mortality [2, 6–7].
To date, there is a paucity of data on the prevalence of CRE isolates in 
the Kingdom of Saudi Arabia. Two recently published studies indicate that CRE 
isolates positive for blaNDM-1 and blaOXA-48 are circulating in hospitals in Riyadh, 
Saudi Arabia [8–9]. This study aimed to determine the prevalence of carbapenem 
resistance as well as evaluate molecular and phenotypic methods for the detec-
tion and characterization of CRE isolates at a large tertiary care hospital in 
 Saudi Arabia.
Materials and Methods
Clinical specimens, bacterial isolates and their identifi cation
This study was carried out between January 2011 and September 2013 at 
the King Khalid University Hospital, Riyadh Saudi Arabia. All ESBL-positive 
isolates identifi ed from routine investigation in the bacteriology laboratory dur-
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ing the study period were included in the study. The isolates were obtained from 
specimens submitted for routine bacteriology investigations. These specimens 
were blood, wound swabs, endotracheal secretions, sputum, body fl uids and 
urine. Isolates were stored at –80 °C for further analysis. Identifi cation of organ-
ism and antimicrobial susceptibility testing were carried out by the MicroScan 
Walkaway 96 plus System (Siemen Healthcare Diagnostic Inc.). ESBL screening 
was carried out by both double disk and E-test according to the Clinical and 
Laboratory Standards Institute (CLSI), 2013 recommended guidelines [10]. Only 
the fi rst representative isolate per patient was included and all other repeat iso-
lates were excluded. Carbapenem resistant but carbapenemase-negative isolates 
were used as negative controls.
Antimicrobial susceptibility testing
Antibiotic susceptibility using the Kirby-Bauer method was carried out on 
Mueller-Hinton agar with commercially available disks from Oxoid in accord-
ance with CLSI guidelines [10]. Antibiotics tested were amikacin (30 μg), gen-
tamicin (10 μg), ciprofl oxacin (5 μg) and sulfamethoxazole (23.75/1.25 μg). The 
minimum inhibitory concentration for imipenem, meropenem, colistin and tige-
cycline was determined by E-test (bioMerieux, Marcy l’Etoile, France) follow-
ing the manufacturer’s instructions and results were interpreted as per CLSI 
guidelines [10]. Escherichia coli ATCC 25922 was used for the quality control. 
All the carbapenem resistant isolates were confi rmed by using modifi ed Hodge 
Test following CLSI guidelines [10].
Phenotypic confi rmation of carbapenemase production
The MASTDISCSTM ID inhibitor combination disk method (Mast Diag-
nostics) for the phenotypic confi rmation of carbapenemases production was 
used according to the manufacturer’s instructions. This methodology utilizes 
four disks: disk A, containing a carbapenem (meropenem, 10 μg); disk B, consist-
ing of meropenem (10 μg) and an MBL inhibitor; disk C, consisting of merope-
nem (10 μg) with a KPC inhibitor; and disk D, containing meropenem (10 μg) 
with an AmpC inhibitor. Interpretation of the test requires comparison of the 
zone of inhibition of disk A with the zones of inhibition of each of disks B, C, 
and D. If disk B shows a zone difference of ≥5 mm from disk A this is indica-
tive of MBL activity. Zone difference of ≥4 mm for disk C compared to disk A, 
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indicates KPC activity. If disk C and disk D show a zone difference of ≥4 and 
≥5 mm, respectively, from disk A, this is indicative of AmpC activity coupled 
with porin loss (impermeability) [11].
Genotypic testing for ESBL and carbapenemases genes
This was carried out using the Check-MDR CT102 DNA microarray 
(CheckPoints BV, Wageningen, Netherlands) at the Antimicrobial Resistance 
 Research Laboratory, Alfaisal University, Riyadh Saudi Arabia. At the time of 
the genotypic testing, the research laboratory was blinded to the fi ndings of 
the phenotypic assays. The Check-MDR CT102 combines ligation-mediated 
 amplifi cation with detection of amplifi ed products on a microarray to detect 
 carbapenemase genes (blaOXA-48, blaNDM, blaIMP, blaVIM and blaKPC), blaCTX-M 
groups (blaCTX-M groups 1, 2 and 9, or combined 8/25), and common ESBL- 
associated single nucleotide polymorphisms in blaTEM and blaSHV variants [12]. 
Whole-cell DNAs were extracted from overnight bacterial cultures using the 
Mo Bio UltraClean™ Microbial DNA Isolation Kit. Microarray assays were 
 performed according to the manufacturer’s instructions with provided tubes 
and  reagents as previously described [12–13].
Determination of clonal relationship
This was carried out using the DiversiLab repetitive extragenic palindro-
mic PCR (rep-PCR) system (bioMérieux). This was carried out only for K. pneu-
moniae which constituted the bulk of our isolates. Briefl y, genomic DNA extrac-
tion and preparation was carried out using the Mo Bio UltraClean™ Microbial 
DNA Isolation Kit. As previously described, the rep-PCR amplifi cation was 
 performed using the DiversiLab Klebsiella fi ngerprinting kit and detection 
done using the microfl uidic LabChip kits on Agilent 2100 bioanalyzer according 
to the manufacturer’s instructions (bioMérieux) [14]. The amplifi ed rep-PCR 
DNA fragment patterns were analyzed with the DiversiLab analysis software 
 using the modifi ed Kullback–Leibler statistical method.
Results
A 883 ESBL-positive Enterobacteriaceae were detected during this peri-
od. A total of 14 isolates suspected to have carbapenemase enzymes were identi-
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Table Ia. Patient demographics, laboratory and clinical details (n = 13)
Gender No. (%)
Male 10 (76.9)
Female  3 (23.1)
Age (Years)
Range (Mean)  1–93 (49)
Source
Wound  5 (38.5)
Sterile Body Fluid  3 (23.1)
Urine  2 (15.4)
Blood  1 (7.7)
Respiratory  1 (7.7)
Unknown  1 (7.7)
Isolates
E. coli  2 (15.4)
K. pneumoniae*  8 (61.5)
K. oxytoca  1 (7.7)
E. cloacae  2 (15.4)
Risk factors
Abdominal surgery  7 (53.8)
Catheterized  6 (46.2)
Clinical presentation
Surgical diseases  6 (46.2)
Acute infections  3 (23.1)
Chronic medical diseases  4 (30.8)
Wards
Internal medicine  5 (38.5)
Surgical  4 (30.8)
Oncology  2 (15.4)
ICUs  2 (15.4)
Outcome
Survived 12 (92.3)
Died  1 (7.7)
*: From Patient #6 two different strains isolated.
ICUs: Intensive care units
74 SOMILY et al.
Acta Microbiologica et Immunologica Hungarica 63, 2016
fi ed. Two isolates (6a and 6b) were obtained from the same patient. Tables Ia and 
Ib show the clinical characteristics of the patients from whom these isolates were 
obtained and the antibiogram of the isolates. The fi ndings of the genotypic test-
ing using the Check-MDR CT102 DNA microarray for the 14 isolates are 
shown in Table II. Twelve isolates were positive for ESBL genes of which there 
were 10blaCTX-M, 6blaTEM and 9blaSHV. Eight isolates were positive for more 
than one ESBL gene (Table II). Of the 10blaCTX-M positive isolates, 7 haboured 
only blaCTX-M1, 2 had only blaCTX-M9, while one isolate harboured both blaCTX-M1 
and blaCTX-M9. Ten isolates were positive for carbapenemase genes of which 5 
were blaNDM-1, 3blaOXA-48 and 3blaVIM-1. One isolate was positive for both blaOXA-48 
and blaVIM-1. Nine isolates were positive for both ESBL and carbapenemase 
genes (Table II). All isolates were negative for blaKPC, blaIMP and blaVIM-2. Com-
parison of genotypic and phenotypic testing for carbapenemase producers re-
vealed that blaVIM-1 positive isolates were detected as NDM-1 on phenotypic 
 testing (Table III). All isolates which were negative for carbapenemase genes 
were also negative for NDM-1 by phenotypic testing. Isolates positive for only 
Table Ib. The antibiogram pattern of isolates
Isolates Imipenem Meropenem Colistin Tigecycline AMK GENT SXT CIP
 1 E. coli  2  1.5  0.25 0.38 I R R R
 2 K. pneumoniae  4  3  0.38 1 S S R I
 3 K. pneumoniae  2  3  0.25 1.5 S S R I
 4 K. oxytoca 32 16  0.19 0.75 R R R S
 5 K. pneumoniae 32  8  0.25 1.5 S R R S
 6a* K. pneumoniae >32 >32  0.38 2 R R R R
 6b* K. pneumoniae >32 >32  0.125 0.25 R R R R
 7 K. pneumoniae >32 >32  0.5 8 R R R R
 9 K. pneumoniae  4  8  0.38 1.5 S R R R
10 K. pneumoniae >32 >32  0.25 2 R R R R
11 E. cloacae complex 32 12  0.125 1 S R R I
12 E. coli  2  1.5  0.25 0.38 I R R R
13 E. cloacae 32 32 16 0.75 S S R R
14 K. pneumoniae 12 R  0.4 0.5 R R R R
AMK: Amikacin; GENT: Gentamicin; SXT: Trimethoprim-sulfamethoxazole; CIP: Ciprofl oxacin
*Two isolates obtained from the same patient
S: Sensitive; I: Intermediate resistant; R: Resistant
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blaOXA-48 were reported as negative on phenotypic testing (Table III). Both 
 phenotypic and genotypic methods were in agreement in the identifi cation of 
2 carbapenem resistant isolates which were negative for carbapenemase genes 
(Table III). The correlation between phenotypic and genotypic tests is show in 
Table IV. Two K. pneumoniae isolates (6a and 6b) were from a single patient. 
These two isolates showed different antibiogram patterns (Table Ib) and geno-
typic characteristics (Table II). Diversilab rep-PCR analysis of the 9 K. pneumo-
Table III. Comparison of genotypic and phenotypic testing for carbapenemase and ESBL
Isolate #
Genotypic testing Phenotypic testing
Hodge’s Test
Carbarpenemase genes KPC NDM AmpC
 1 – – – – Negative
 2 NDM-1 – + – Negative
 3 NDM-1 – + – Negative
 4 OXA-48; VIM-1 – + – Positive
 5 VIM-1 – + – Positive
 6a NDM-1 – + – Negative
 6b OXA 48 – – – Positive
 7 NDM-1 – + – Negative
 9 NDM-1 – + – Negative
10 OXA 48 – – – Positive
11 VIM1 – + – Positive
12 – – – – Negative
13 – – – + Negative
14 OXA 48 – – – Positive
+: positive; –: negative
Table IV. Correlation between phenotypic and genotypic methods for detection of carpeneamases
NEG
MBL
OXA-48 Total
NDM VIM
Interpretation
AmpC 1 0 0 0  1
MBL 0 5 3 1  8
NEG 2 0 0 3  5
Total 3 5 3 4 14
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niae isolates revealed distribution into eight clusters supportive of a polyclonal 
origin of these isolates in our setting (Fig. 1). The two K. pneumoniae isolates 
(6a and 6b) obtained from the same patient were clustered into two different 
groups (Groups 1 and 2) on the basis of rep-PCR patterns (Fig. 2).
Discussion
We have described the molecular epidemiology of carbapenemase resist-
ance genes and comparison of detection methods of such mechanism in Entero-
bacteriaceae. Although the prevalence of CRE (1.6%) in our study is lower 
 compared to other reported data [15–16], the risk factors and CRE clinical infec-
tions seen in our patients are in keeping with reported literature [17]. The most 
prevalent mechanism of carbapenem resistance among Enterobacteriaceae is 
the acquisition of carbapenemases with KPC-, NDM-, and OXA-48-type en-
zymes being the commonest [18]. In our study the predominant mechanism of 
carbapenem resistance was due to NDM enzyme with prevalence similar to 
 data from India where 31%–55% of Enterobacteriaceae isolates were reported 
to be NDM producers [19–20]. However, it is higher than the 5%–18.5% in 
 Indian and Pakistani hospitals reported by Dortet et al. [21]. This disparity is 
Figure I. Diversilab rep-PCR analysis of K. pneumoniae isolates.
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 attributable to geographical variation, isolates number studied and detection 
method. Within our region, sporadic reports of NDM producers have been re-
ported in hospitals in neighbouring countries of the Arabian Gulf region and its 
international transfer from patients previously hospitalized in the Middle East 
have been reported [22–23].
The OXA-48 carbapenemases which were fi rst described in K. pneumo-
niae epidemic isolates from Turkey have now superseded VIMs and IMPs as 
the most common MBLs [24]. Genes for OXA-48 and related enzymes are pre-
sent widely in North Africa, the Middle East and the Indian subcontinent refl ect-
ing the high level of occurrence we have observed [25]. For three isolates (two 
E. coli and one E. cloacae) no carbapenemase activity was identifi ed suggest-
ing a non-carbapenemase related resistance mechanism. The two E. coli isolates 
genetically demonstrated blaCTX-M1 gene with probable hyperproduction along 
with porin loss being responsible for apparent carbapenem resistance. However, 
it was quite interesting to witness E. cloacae carbapenem resistance in our study 
which apparently lacked any of the tested ESBLs and carbapenemase genes and 
we speculate that the resistance might be via porins loss or effl ux mechanism. 
None of the isolates was found to produce the KPC, or IMP type beta lactamase, 
although these enzymes have been previously documented in Saudi Arabia 
and Kuwait [26–27]. Our Diversilab rep-PCR analysis of the 9 K. pneumoniae 
isolates revealed a polyclonal origin of these isolates. Two K. pneumoniae clones 
from the same patient (one harboured blaNDM-1 gene and the other blaOXA-48 gene) 
were resistant to amikacin, gentamicin, ciprofl oxacin and cotrimoxazole but 
 susceptible to colistin and tigecycline. This phenomenon is rare and could be 
 attributed to plasmid transfer.
Our evaluation of the phenotypic confi rmation test (MHT) and commer-
cial system (MASTDISCSTM ID inhibitor combination disks) for the detection of 
carbapenemase production in Enterobacteriaceae showed that in keeping with 
previous report, the MDI disks detected all MBL positive isolates with 100% 
agreement with molecular genotyping data [11]. However, MDI disks are not de-
signed to detect class D enzymes like OXA-48 and one isolate (#4) which coex-
pressed VIM and OXA-48 was identifi ed as MBL. Although the MHT assay reli-
ably detects KPC and OXA-48 producers it performs poorly in the detection of 
MBL producers and this is refl ected in our fi ndings as none of the NDM-1 was 
detected by MHT [28]. Therefore for the optimal detection of CRE we recom-
mend the use of molecular based methods. However, in resource-limited settings, 
a combination of the two phenotypic tests we have evaluated is a good alterna-
tive. The MASTDISCSTM will identify KPC and NDM producers, while the mod-
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ifi ed Hodge test will ensure that OXA-48 producers are detected. This will pro-
vide a cost-effective and rapid approach for the detection of carbapenemases in 
Enterobacteriaceae.
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